FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

View source ↗

Summary

FDA approves Otarmeni (lunsotogene parvec-cwha), the first dual AAV vector-based gene therapy for genetic hearing loss under the National Priority Voucher progr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Hearing Loss

Drugs mentioned

• Otarmeni (lunsotogene parvec-cwha)

Snippet

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.